52-Week High Screen: Cupid, Honasa at Range Peak

Cupid at 98% and Honasa Consumer at 97% of their 52-week range show repriced expectations in Indian midcap consumption.

market · 16 September 2026 · 4 min read

52-Week High Screen: Cupid, Honasa at Range Peak
A 52-week high screen strips away narrative. It shows where the market has already placed its money. The latest run through Indian midcaps shows Cropster Agro and Bondada Engineering at 100% of their annual range. Balmer Lawrie Investment also sits at 100%. Cupid is at 98%. Honasa Consumer is at 97%. The readings are not predictions. They are evidence of repriced expectations, especially in domestic consumption and specialty engineering. For investors, the screen is a map of crowded trades. It flags stocks where the entry price now includes most public information. [Cupid](/stock/CUPID) (NSE: CUPID) and [Honasa Consumer](/stock/HONASA) (NSE: HONASA) stand out because their moves are recent, retail-heavy and partly driven by a rotation into smallcap and midcap earnings stories. 52-Week High Screen: What the Numbers Show Cupid, a contraceptive and personal care manufacturer, has moved from a thinly followed smallcap to a momentum name. The stock trades at 98% of its 52-week range. In practical terms, that means there is almost no overhead supply inside the rolling annual window. Buyers have absorbed nearly every seller from the last 12 months. That is a strong statement about sentiment, not necessarily a statement about valuation. Honasa Consumer, the parent of Mamaearth and The Derma Co, has reached 97% of its annual range. The move follows a difficult period of trade channel correction after the company's post-IPO expansion into general trade. Inventory overstocking had dented revenue growth. The current range reading suggests investors are now treating the channel reset as largely complete. The stock's recovery has been sharp, and that sharpness carries its own risk. Sector Impact of Range Peaks in Cupid and Honasa Cupid's rise fits a broader theme in Indian midcap healthcare and rubber consumables. Contract manufacturing and branded condom sales have drawn attention as domestic production costs stay competitive. The company has expanded capacity in Maharasht...

AI-generated market intelligence. Not investment advice.